Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.46 - $0.81 $36,098 - $63,563
-78,474 Reduced 84.14%
14,795 $9,000
Q4 2022

Feb 14, 2023

BUY
$0.5 - $261.0 $13,388 - $6.99 Million
26,776 Added 40.27%
93,269 $60,000
Q3 2022

Oct 26, 2022

BUY
$1.04 - $322.5 $69,152 - $21.4 Million
66,493 New
66,493 $78,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.